Newer antipsoriatic biologics, including interleukin-17 (IL-17) inhibitors have revolutionized the management of moderate to severe psoriasis due to their unprecedented disease control and favorable safety profile. With increased use in the real world, adverse events not previously described in large phase III clinical trials are being recognized.
FBI Reform - fbireform.comFBI Reform - fbireform.com - The News And Times